Stock code: 000963 Stock abbreviation: Huadong Medicine Announcement No.: 2026-030
Huadong Medicine Co., Ltd. First Quarterly Report 2026
The Company and all members of the Board of Directors hereby guarantee that the information presented in this report is authentic, accurate and complete and free of any false records, misleading statements or material omissions.
Important Declaration:
1. The Board of Directors, directors and senior management of Huadong Medicine Co., Ltd. (hereinafter referred to as the "Company") hereby guarantee that the information presented in the Report is authentic, accurate and complete and free of false records, misleading statements or material omissions, and shall undertake individual and joint legal liabilities
2. The Company's legal representative, the officer in charge of accounting, and the head of Accounting Department (accounting manager) hereby declare that the financial information in this quarterly report is authentic, accurate and complete.
3. Has the First Quarterly Report been audited?
□Yes No
According to “Stock Listing Rules of the Shenzhen Stock Exchange”, if listed companies have both Chinese and other language version of public notice, they should ensure the content of both versions are the same. In the case of discrepancy, the origina version in Chinese shall prevail.
I. Key Financial Data
(I) Key accounting data and financial indicators
Whether the Company needs to perform a retroactive adjustment or restatement of previous accounting data
| Current reporting period | Same period last year | Year-on-year change for the reporting period (%) | |
| Operating revenue (RMB) | 11,183,450,824.27 | 10,735,787,899.82 | 4.17% |
| Net profits attributable to shareholders of the listed company (RMB) | 1,002,189,357.16 | 914,708,484.70 | 9.56% |
| Net profits attributable to shareholders of the listed company after deduction of non-recurring profit and loss (RMB) | 989,719,668.99 | 897,337,982.42 | 10.30% |
| Net cash flow from operating activities (RMB) | -852,335,762.63 | -832,728,693.88 | -2.35% |
| Basic earnings per share (RMB/share) | 0.5715 | 0.5224 | 9.40% |
| Diluted earnings per share (RMB/share) | 0.5715 | 0.5213 | 9.63% |
| Weighted average return on equity | 3.97% | 3.88% | 0.09% |
| End of the current reporting period | End of the last year | Change from prior year-end (%) | |
| Total assets (RMB) | 39,908,042,564.94 | 39,038,036,320.92 | 2.23% |
| Owners' equity attributable to shareholders of listed companies (RMB) | 25,733,074,032.10 | 24,811,339,992.99 | 3.71% |
The Company's total share capital as of the trading day prior to disclosure:
| The Company’s total share capital as of the trading day prior to disclosure (shares) | 1,753,736,848.00 |
| Fully diluted earnings per share based on the latest share capital: | |
| Preferred dividends paid (RMB) | 0.00 |
| Paid perpetual bond interest (RMB) | 0.00 |
| Fully diluted earnings per share based on the latest share capital (RMB/share) | 0.5715 |
(II) Non-recurring profit and loss items and amounts
Applicable □Not applicable
Unit: RMB
| Item | Amount during the current reporting period | Description |
| Profits/losses on disposal of non-current assets (including the written-off part of the accrued impairment provision of assets) | 534,949.84 | |
| Government grants included in the | 22,334,120.97 |
Explanation for recognizing an item listed as a non-recurring profit and loss in the Interpretative Announcement No. 1 on Information Disclosure Criteria for Public Listed Companies - Non-Recurring Profits and Losses as an item of recurring profit and loss
Unit: RMB 10,000
| current profits and losses (except those that are closely related to the normal business operation of the Company, comply with national policies and regulations, are enjoyed in accordance with the defined criteria, and have a lasting impact on the Company's profits and losses) | ||
| Other non-operating revenue and expenses other than those mentioned above | -7,779,473.38 | |
| Less: Amount affected by income tax | 1,182,827.86 | |
| Amount affected by minority interests (after tax) | 1,437,081.40 | |
| Total | 12,469,688.17 | -- |
Details of other profit and loss items conforming to the definition of non-recurring profits and losses □Applicable Not applicable There are no other profit and loss items that meet the definition of non-recurring profits and losses.
□Applicable Not applicable
The Company did not recognize any item of non-recurring profit and loss items listed in the Interpretative Announcement No. 1 on Information Disclosure Criteriafor Public Listed Companies - Non-Recurring Profits and Losses as an item of recurring profit and loss.
(III) Details and reasons for changes in key accounting data and financial indicators
Applicable □Not applicable
| Items in the balance sheet | Closing balance | Opening balance | Percentage change | Reasons for changes |
| Notes receivable | - | 621.34 | -100.00% | Mainly attributable to the decrease in commercial acceptance bills receivable during the current period |
| Other current assets | 13,927.49 | 22,234.33 | -37.36% | Mainly attributable to the decrease in creditable VAT input tax at the end of the period |
| Other current liabilities | 3,494.29 | 1,044.36 | 234.59% | Mainly attributable to the increase in VAT output tax pending carryover during the current period |
| Employee compensation payable | 23,713.85 | 41,159.88 | -42.39% | Mainly attributable to remuneration paid during the current period |
| Other comprehensive income | -7,483.69 | 577.07 | -1396.85% | Mainly attributable to changes in foreign currency translation differences during the current period |
| Items in the income statement | Amount in the current period | Amount in the previous period | Percentage change | Reasons for changes |
| R&D expenses | 35,036.53 | 51,537.69 | -32.02% | Key programs were progressed smoothly in clinical studiesduring the period. Expenditures related to Phase III clinical programs met the capitalization criteria and were capitalized during the current period, resulting in a corresponding decrease in R&D expenses |
| Financial expenses | -472.53 | 1,461.80 | -132.33% | Mainly attributable to the increase in exchange earning in the current period |
| Investment income | -2,231.03 | -4,262.41 | 47.66% | Mainly attributable to the increase in investment income recognized from associates in the current period |
| Other income | 3,123.03 | 7,364.16 | -57.59% | Mainly attributable to the decrease in government grants during the current period |
| Proceeds from disposal of assets | 53.49 | -1,454.10 | 103.68% | Mainly attributable to the decrease in net losses from asset disposal during the current period |
| Non-operating expenses | 909.54 | 2,807.54 | -67.60% | Mainly attributable to the decrease in external donations made during the current period |
| Items in the cash flow statement | Amount in the current period | Amount in the previous period | Percentage change | Reasons for changes |
| Net cash flows from investing activities | -39,140.04 | -64,583.94 | 39.40% | Mainly attributable to the decrease in investment in the current period |
| Net cash flow from financing activities | 3,521.20 | -8,683.86 | 140.55% | Mainly attributable to the year-on-year decrease in the repayment of interest-bearing liabilities |
II. Shareholder Information
(I) Total number of common shareholders, number of preferred shareholders with restored voting rights and shareholdings of top 10 shareholders
Unit: Shares
| Total number of common shareholders at the end of the reporting period | 84,304 | Total number of preferred shareholders with restored voting rights at the end of the reporting period (if any) | 0 | |||
| Particulars about the top 10 shareholders (excluding shares lent through refinancing) | ||||||
| Name of shareholder | Nature of shareholder | Shareholding ratio (%) | Number of shares held | Number of shares held with trading restrictions | Pledged, marked or locked-up status | |
| Status of shares | Quantity | |||||
| China Grand Enterprises, Inc. | Domestic non-state-owned corporation | 41.68% | 730,938,157 | 0 | Pledged | 138,640,000 |
| Hangzhou Huadong Medicine Group Co., Ltd. | State-owned corporation | 16.42% | 288,000,000 | 0 | Not applicable | 0 |
| Hong Kong Securities | Overseas corporation | 2.22% | 38,923,330 | 0 | Not applicable | 0 |
| Clearing Company Limited | ||||||
| New China Life Insurance Co., Ltd. - Dividend - Individual Dividend - 018L-FH002 Shenzhen | Others | 2.05% | 35,903,842 | 0 | Not applicable | 0 |
| New China Life Insurance Co., Ltd. - Traditional - General Insurance Products - 018L-CT001 Shenzhen | Others | 1.32% | 23,204,014 | 0 | Not applicable | 0 |
| Industrial and Commercial Bank of China Limited - Zhong Ou AMC Medical and Health Hybrid Securities Investment Fund | Others | 1.21% | 21,182,329 | 0 | Not applicable | 0 |
| China Securities Finance Corporation Limited | Domestic non-state-owned corporation | 1.09% | 19,095,344 | 0 | Not applicable | 0 |
| National Social Security Fund - Portfolio 112 | Others | 1.00% | 17,589,744 | 0 | Not applicable | 0 |
| Bank of Shanghai Co., Ltd. - Yinhua CSI Innovative Pharmaceutical Industry Traded Open-ended Index Securities Investment Fund | Others | 0.74% | 13,013,898 | 0 | Not applicable | 0 |
| China Construction Bank Corporation - E Fund CSI 300 Medical and Health Trading Open IndexSecurities Investment Fund | Others | 0.70% | 12,343,870 | 0 | Not applicable | 0 |
| Information about the top 10 shareholders without trading restrictions (excluding shares lent through conversions and locked-up shares for senior management) | ||||||
| Name of shareholder | Number of shares held without trading restrictions | Type of shares | ||||
| Type of shares | Quantity | |||||
| China Grand Enterprises, Inc. | 730,938,157 | RMB common shares | 730,938,157 | |||
| Hangzhou Huadong Medicine Group Co., Ltd. | 288,000,000 | RMB common shares | 288,000,000 | |||
| Hong Kong Securities Clearing Company Limited | 38,923,330 | RMB common shares | 38,923,330 | |||
| New China Life Insurance Co., Ltd. - Dividend - Individual Dividend - 018L-FH002 Shenzhen | 35,903,842 | RMB common shares | 35,903,842 | |||
| New China Life Insurance Co., Ltd. - Traditional - General Insurance Products - 018L-CT001 Shenzhen | 23,204,014 | RMB common shares | 23,204,014 | |||
| Industrial and Commercial Bank of China Limited - Zhong Ou AMC Medical and Health Hybrid Securities Investment Fund | 21,182,329 | RMB common shares | 21,182,329 | |||
| China Securities Finance Corporation Limited | 19,095,344 | RMB common shares | 19,095,344 | |||
| National Social Security Fund - Portfolio 112 | 17,589,744 | RMB common shares | 17,589,744 | |||
| Bank of Shanghai Co., Ltd. - Yinhua CSI Innovative Pharmaceutical Industry Traded Open-ended Index Securities Investment Fund | 13,013,898 | RMB common shares | 13,013,898 | |||
| China Construction Bank Corporation - E Fund CSI 300 Medical and Health Trading Open Index Securities Investment Fund | 12,343,870 | RMB common shares | 12,343,870 | |||
| Explanation on associated relationships or concerted actions among the above-mentioned shareholders | The Company is unaware of whether the above-mentioned shareholders are related parties or whether they are concert parties with one another. | |||||
| Description of the participation in securities margin trading business of top 10 shareholders (if any) | As of the end of the current reporting period, none of the top 10 common shareholders of the Company held shares of the Company through securities margin trading accounts. | |||||
Participation in the lending of shares through refinancing business of shareholders holding more than 5% of shares, top 10 shareholders and top 10 shareholders holding tradable shares without trading restriction
□Applicable Not applicable
Change in top 10 shareholders and top 10 shareholders holding tradable shares without trading restriction due to lending/returning of shares through refinancing as compared to the previous period
□Applicable Not applicable
(II) Total number of preferred shareholders and shareholding list of top 10 preferred shareholders of the Company
□Applicable Not applicable
Ⅲ. Other Important Matters
Applicable □Not applicable
(I) Overview of the Company's overall operations during the reporting period
In 2026, external competition is expected to continue intensifying, and the policy environment has become increasingly complex and volatile. Corporate development faces mounting pressures. Competition driven by market share will enter a new stage. During the reporting period, in the face of these challenges, the Company has remained firmly aligned with its overall strategic roadmap and annual operational objectives. Guided by the business priorities of "exploring new markets, focusing on new products, strengthening organizational capabilities, and building new competencies", the Company has upheld the management philosophy of "problem-solving and value creation", and integrated the principles of "innovation-driven development, resource integration, and enterprise-wide collaboration" throughout all operational processes; staying committed to its innovation, the Company has systematically advanced comprehensive upgrades across its product portfolio, management systems, and talent development. It concentrated resources on tackling key R&D and clinical study programs, deepened collaboration across sectors such as pharmaceuticals, medical aesthetics, and commercial operations, continuously activated growth drivers for innovative business, and realized steady improvements in operational quality and management efficiency, ensuring the orderly execution of various tasks.
During the reporting period, the Company achieved operating revenue of RMB 11.183 billion, representing a YoY increase of 4.17% and a quarter-on-quarter increase of 2.15% compared with Q4 2025. Net profit attributable to shareholders of the listed company reached RMB 1.002 billion, up 9.56% year-on-year. Net profit attributable to shareholders excluding non-recurring profit and loss items was RMB 990 million, marking a YoY increase of 10.30% and reaching a historical high for the same period.
During the reporting period, Zhongmei Huadong, the Company's core subsidiary in the field of pharmaceutical industry, maintained steady growth in overall operations. It achieved operating revenue (including CSO business) of RMB 4.048 billion, representing an 11.82% YoY increase. The consolidated net profit attributable to the parent company reached RMB 931 million, up 10.44% year-on-year. Both operating revenue and net profit attributable to the parent company recorded the growth exceeding 10%.
During the reporting period, the revenue contribution of innovative products continued to increase. Sales and agency service revenue generated from innovative products reached RMB 810 million, representing a year-on-year growth of 61.8% and accounting for 20.05% of the operating revenue of the pharmaceutical industry segment (including the CSO business). The overall business of the Company has entered a strong growth trajectory, further demonstrating the effectiveness of the Company’s R&D achievement transformation and the professionalism of its commercialization operations. By the end of the first quarter of 2026, medical institutions that were certified and registered to administer the CAR-T therapy Zevorcabtagene Autoleucel Injection (zevor-cel) had expanded to more than 20 provinces and municipalities across the country. Zevor-cel has also been included in the Commercial Health Insurance Innovative Drug List. As of the date of this Report, more than 100 commercial and Huiminbao (a city-specific supplemental medical insurance program) programs have incorporated zevor-cel into their reimbursement coverage. Since its launch, Sailexin<sup>®</sup>, the biosimilar of Ustekinumab Injection, has demonstrated outstanding market performance. To date, it has been prescribed in over 2,000 hospitals, and its sales revenue in the first quarter of 2026 increased by nearly 200% year on year.
In the diabetes field, Huiyoujing<sup>®</sup>, i.e., Ganagliflozin Proline Tablets, which is the Class 1 new drug, has now been adopted by over 1,900 tiered hospitals. Its sales revenue in the first quarter of 2026 increased by over 800% year on year (noting that the first quarter of 2025 was its first sales period after inclusion in the national reimbursement drug list).
By the end of the first quarter, Mirvetuximab Soravtansine Injection (trade name: ELAHERE<sup>®</sup>) had been listed on drug procurement platforms in 29 provinces, prescribed in over 200 hospitals, and made available in more than 400 medical institutions and over 200 DTP pharmacies. Currently, Elahere<sup>®</sup> has also been successfully incorporated in multiple Huiminbao (a city-specific supplemental medical insurance program) programs and commercial insurance programs, such as Beijing Inclusive Medical Insurance Program, Jiangxi Ganhuibao (inclusive commercial health insurance program), Leshan Huijiabao (city-customized insurance program), and Shaanxi Universal Health Insurance. From 2025 to the end of the reporting period, cumulative sales of Elahere<sup>®</sup> exceeded RMB 100 million. The novel PARP inhibitor, Senaparib Capsules (trade name: Paishuning<sup>®</sup>), exclusively promoted by the Company, has delivered outstanding market performance. Currently, it is available in over 300 DTP pharmacies and more than 900 medical institutions, supported by a multi-tier distribution network; at the same time, the Company actively promoted the inclusion of its product in reimbursement coverage of insurance programs. The product has been incorporated into multiple regional Huiminbao programs (e.g., West Lake Yilianbao, Huhuibao, Chonghuibao, Jiaxing Huiminbao, and CPIC-Huxiangbao), as well as other commercial insurance programs, effectively reducing the financial burden of patients.
MediBeacon<sup>®</sup> TGFR, the world’s first bedside renal function assessment device applicable to patients with normal or impaired renal function , has officially commenced commercial sales in the Chinese market. To date, consumables of MediBeacon<sup>®</sup> TGFR have been listed in 25 provinces, while Relmapirazin Injection has been listed in 21 provinces.
During the reporting period, the pharmaceutical distribution segment of the Company sustained stable operations, yielding an aggregate operating revenue of RMB 7.181 billion, marking a year-on-year (YoY) uptick of 3.57%, and a net profit of RMB 119 million, representing a 3.16% YoY increase. Overall, it demonstrated a robust developmental trajectory.
Affected by multiple factors such as the cyclical fluctuations in the global economy, intensified industry competition, and slower-than-expected recovery in domestic aesthetic medicine consumption, the Company's aesthetic medicine segment continued to confront growth headwinds. Throughout the reporting period, it achieved a total operating revenue of RMB 361 million (excluding internal offsets), reflecting a YoY decline of 30.38%.
On March 25, 2026, the Company's exclusively distributed product, Recombinant Botulinum Toxin Type A for Injection (R&D code: YY001; trade name: Retoxin<sup>®</sup>), received marketing approval from the National Medical Products Administration (NMPA). This product is indicated for the temporary amelioration of moderate-to-severe glabellar lines in adults aged 65 and under, resulting from the activity of the corrugator supercilii and/or procerus muscles. This product is poised to initiate formal commercial sales in the near future.
During the reporting period, the Company's industrial microbiology segment continued to experience relatively rapid revenue growth, with a YoY increase of 21.82%. Given the proactive expansion into overseas markets and a consistent uptick in orders, this segment is anticipated to uphold its favorable developmental momentum.
(II) Important R&D progress of the Company during the reporting period
1. Major progress in innovation-driven R&D during the reporting period
Oncology
HDM2005, an antibody-drug conjugate (ADC) targeting ROR1, has maintained its leading position within the global first echelon of clinical development for ROR1 ADCs. Presently, three clinical studies are being conducted in China: a Phase I clinical study evaluating monotherapy for advanced hematologic malignancies, including mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and classical Hodgkin lymphoma (cHL). This study has completed Phase Ia monotherapy dose escalation and is currently performing dose expansion studies for MCL and cHL. Another Phase I study, assessing monotherapy for advanced solid tumors, has enrolled 17 patients and is conducting dose expansion at a dosage of 2.5 mg/kg. Additionally, a Phase Ib &II clinical study investigating combination therapy for DLBCL patients is currently undergoing combination therapy dose escalation. In addition, the Company has submitted communication and meeting requests to the CDE, respectively, for combination therapy in MCL and cHL.
The clinical study for dose escalation of monotherapy involving HDM2020, an ADC targeting FGFR2b, has advanced to the fourth dose cohort. Furthermore, a Phase Ia study for lung squamous cell carcinoma has officially commenced, with subject screening currently in progress. In February 2026, HDM2020 was granted orphan drug designation (ODD) by the U.S. FDA for gastric cancer (including gastroesophageal junction cancer).
HDM2012, an ADC targeting MUC17, has reached the fourth dose cohort in its Phase I clinical study aimed at treating advanced solid tumors.
HDM2017, targeting CDH17, has progressed to the fourth dose cohort in its Phase Ia monotherapy trial in China, with concurrent dose expansion at a dosage of 3.2 mg/kg. The first Australian site was activated in February 2026, and subject screening is ongoing. In addition, in March 2026, HDM2017 received ODD from the U.S. FDA for three indications: biliary tract cancer, gastric cancer, and pancreatic cancer.
HDM2024, an EGFR/HER3-targeting bispecific ADC, received IND approvals in the United States and China in March 2026 for the treatment of advanced solid tumors. The first subject administration in a Phase I clinical study in China was completed in April 2026.
HDP-101 (HDM2027), a BCMA-targeting amanitin ADC, enrolled its first patient in China in March 2026 for the treatment of plasma-cell disorders, including multiple myeloma.
The small-molecule antineoplastic agent HPK-1 PROTAC (hematopoietic progenitor kinase 1 proteolysis-targeting chimera), HDM2006 tablets, is currently undergoing a Phase I clinical study in China for the treatment of advanced solid tumors, with enrollment for the third dose cohort underway.
DR30206 for injection, a proprietary PD-L1/VEGF/TGF-β tri-specific antibody fusion protein, developed by Doer Biologics, a controlled subsidiary of the Company, is nearing the completion of dose expansion studies in its Phase Ib trial for the first-line treatment of non-small cell lung cancer, demonstrating promising overall efficacy. The program is advancing its combination therapy study. Phase Ib/IIa clinical studies evaluating combination therapy with standard chemotherapy for advanced or metastatic gastrointestinal tumors, as well as Phase Ib monotherapy expansion studies for head and neck squamous cell carcinoma cohorts, are currently underway. In January 2026, the DR30206 was administered to the first subject in the monotherapy expansion cohort for platinumresistant ovarian cancer during its Phase Ib trial. In March 2026, DR30206 received IND approval in China for its combination with standard chemotherapy in patients with locally advanced or
metastatic non-small cell lung cancer.
Endocrinology
HDM1002 (conveglipron), the oral small-molecule GLP-1 receptor agonist, has completed enrollment of all subjects for its Phase III clinical study in China for the weight management indication. The study is currently in the stage of treatment follow-up and data collection. The NDA application is expected to be submitted in Q4 2026. Both Phase III clinical studies for the type 2 diabetes mellitus indication of this product have completed full enrollment. Pre-NDA communication application is expected to be submitted in Q4 2026.
HDM1005 (poterepatide) Injection, a GLP-1R/GIPR long-acting polypeptide dual-target agonist, enrolled all subjects in the Phase III clinical study for the weight management indication. Top-line results for the Phase II clinical study for diabetes were obtained in February 2026. The first subjects have been enrolled in both Phase III studies for diabetes. Two Phase III studies for the obstructive sleep apnea hypopnea syndrome (OSAS) indication are currently in preparation.
DR10624, a first-in-class therapeutic candidate targeting FGF21R/GCGR/GLP-1R and developed by Doer Biologics, a controlled subsidiary of the Company, is currently progressing with preparations for its Phase III clinical study aimed at treating severe hypertriglyceridemia. In January 2026, DR10624 was included in the Breakthrough Therapy Designation by the CDE for severe hypertriglyceridemia. The Phase II clinical study targeting patients with metabolic dysfunctionassociated steatotic liver disease with high risk of liver fibrosis is currently being conducted concurrently. Top-line results are expected to be obtained in Q3 2026.
HDM1014 injection, which is the GalNAc-siRNA weight-loss drug self-developed by the Company, is undergoing IND development work. It is expected to submit IND application in China in Q4 2026.
The IND application for HDM1010 tablets (a fixed-dose oral combination formulation of HDM1002) intended for the treatment of type 2 diabetes mellitus has received approval from the U.S. FDA. Clinical study preparations are currently in full swing.
The NDA for the diabetes indication of Semaglutide Injection was submitted and accepted in March 2025 and successfully passed clinical inspection; the NDA for the weight management indication was accepted in April 2026.
The NDA for Insulin Degludec Injection was submitted and accepted in February 2025; the on-site inspection has been completed, and the application is currently under technical review.
The top-line results from the Phase III clinical study of Insulin Degludec and Insulin Aspart Injection have been obtained. It is expected to submit NDA in the Q2 of 2026.
Autoimmunity
The Marketing Authorization Application (MAA) and supplemental application for HDM3001 (QX001S), a ustekinumab biosimilar developed in collaboration with Qyuns Therapeutics for the treatment of Crohn's disease, are expected to receive approval in the Q2 of 2026.
The Phase III clinical studies for the innovative drug Oturkibart (R&D code: HDM3016/QX005N), which was developed by the Company in collaboration with Qyuns Therapeutics for the treatment of prurigo nodularis (PN) and atopic dermatitis (AD) have reached their primary endpoints. The NDAs for the PN and AD indications are expected to be submitted in the first and second halves of 2026, respectively.
The Chinese NDA applications for HDM3014 (Roflumilast Cream), developed in collaboration with Arcutis in the United States for two indications—plaque psoriasis in patients aged 6 and above, and atopic dermatitis in patients aged 6 and above—have successfully passed the clinical on-site inspection conducted by the National Medical Products Administration. In addition, the Chinese NDA application for Roflumilast Cream for atopic dermatitis indication in patients aged 2 to 5 was accepted in February 2026.
The Phase I/II clinical study evaluating Ruxolitinib Gel (HDM3010), a modified new drug developed by the Company, for the treatment of prurigo nodularis has yielded top-line results. The Company has received feedback from the Center for Drug Evaluation (CDE) and are currently making preparations for subsequent studies based on this feedback. In addition, a Phase III clinical study in vitiligo is currently ongoing.
The Phase III clinical study of MC2-01 Cream, developed through a collaboration between the Company and MC2 Therapeutics for the treatment of plaque psoriasis, has enrolled more than 120 subjects in China to date.
HDM4002 Injection, the first-in-class bispecific antibody candidate independently developed by the Company, is currently undergoing IND-enabling development. It is anticipated that IND applications will be submitted in both China and the United States in 2026.
Other segments
The NDA for Ranibizumab Injection was submitted and accepted in May 2025. Subsequently, the on-site inspection has been completed for the production. Ranibizumab Injection has successfully passed the clinical on-site inspection conducted by the National Medical Products Administration.
2. Registration milestones for key innovative products since 2026
| Type | Item | Category | China Registration Class | Milestone Event |
| acceptance | SAILEXIN®(Ustekinumab Injection) | Biosimilar | Class 3.3therapeutic biological product | Supplemental application for new strengthsof Crohn's disease was accepted in January 2026 |
| 0.05% Roflumilast Cream | Innovative drug | Class 5.1 chemical drug | NDA was accepted in February 2026 | |
| Semaglutide Injection | Biosimilar | Class 3.3 therapeutic biological product | NDA for weight management indication was accepted in April 2026 | |
| Budesonide and Fomoterol Powder for Inhalation (IV), Capsule type | Modified new drug | Class 2.2 chemical drug | NDA accepted in April 2026 | |
| IND approved | DR10624 | Innovative drug | Class 1 therapeutic biological product | The IND for metabolic dysfunction-associated steatotic liver disease was approved in the U.S. in January 2026 |
| HDM2005 | Innovative drug | Class 1 therapeutic biological product | The IND for the combination therapy with Rituximab and Lenalidomide for the treatment of relapsed/refractory mantle cell lymphoma was approved in China in January 2026 | |
| DR10624 | Innovative drug | Class 1 therapeutic biological product | IND for hypertriglyceridemia approved in China in February 2026 | |
| DR30206 | Innovative drug | Class 1 therapeutic biological product | The IND for combination with standard chemotherapy in locally advanced or metastatic non-small cell lung cancer patients was approved in China in February 2026 | |
| HDM2024 | Innovative drug | Class 1 therapeutic biological product | The IND for advanced malignant solid tumors was approved in China in March 2026 | |
| HDM2024 | Innovative drug | Class 1 therapeutic biological product | The IND for advanced malignant solid tumors was approved in the U.S. in March 2026 | |
| Orphan drug designation | HDM2020 | Innovative drug | Class 1 therapeutic biological product | Orphan drug designation was granted in the U.S. in February 2026 for indications of gastric cancer and gastroesophageal junction cancer |
| HDM2017 | Innovative drug | Class 1 therapeutic biological product | Orphan drug designation was granted in the U.S. in March 2026 for biliary tract cancer indication | |
| HDM2017 | Innovative drug | Class 1 therapeutic biological product | Orphan drug designation was granted in the U.S. in March 2026 for gastric cancer indication | |
| HDM2017 | Innovative drug | Class 1 therapeutic biological product | Orphan drug designation was granted in the U.S. in March 2026 for pancreatic cancer indication | |
| Breakthrough therapy | DR10624 | Innovative drug | Class 1 therapeutic biological product | Chinese breakthrough therapy designation was obtained in January 2026 for severe hypertriglyceridemia |
Note: Budesonide and Fomoterol Powder for Inhalation (IV)(capsule type) is the product exclusively commercialized by the Company in the Chinese mainland.
3. The Company's pharmaceutical innovation achievements presented at international academic conferences since 2026
| No. | Date of release | Item | Conference/journal name | Presentation format | Title |
| 1 | March 2026 | HDM3014 | American Academy of Dermatology(AAD) | Oral | Efficacy and Safety of Roflumilast Cream 0.3% in Chinese Adult andPediatric Patients with Plaque Psoriasis: Results From a Phase 3 Trial |
| 2 | March 2026 | HDM3014 | American Academy of Dermatology (AAD) | Poster presentation | Roflumilast Cream 0.15% for Mild-to-Moderate Atopic Dermatitis: A Multicenter, vehicle-Controlled Phase 3 Bridging Study in China |
| 3 | March 2026 | HD-NP-102 | Society of Critical Care Medicine (SCCM) | Oral | Clinical Validation of a Transdermal GFR Measurement System in Chinese Individuals |
| 4 | March 2026 | HD-NP-102 | Society of Critical Care Medicine (SCCM) | Oral | Bioequivalence and Efficacy Study of MB-102 With Transdermal GFR Measurement in Chinese Subjects |
| 5 | April 2026 | HDM2021 | American Association for Cancer Research (AACR) | Poster presentation | HDM2021, a potent and selective CBL-B inhibitor exhibits robust immunomodulatory efficacy for anti-tumor therapy |
| 6 | April 2026 | HDM2024 | American Association for Cancer Research (AACR) | Poster presentation | A novel EGFR and HER3 bispecific antibody-drug conjugate exhibits superior antitumor activity and favorable toxicological profile |
| 7 | April 2026 | DR319 | American Association for Cancer Research (AACR) | Poster presentation | DR319-DP: A Nectin-4/Trop-2 bispecific ADC with an avidity-driven VHH design and dual-MOA payloads |
(III) Activities such as research, communication, and interviews conducted during the reporting period
| Reception date | Reception address | Reception method | Type of visitor | Visitors | Main content of discussion and information provided | Index of basic information of the research |
| January 21 and 22, 2026 | Conference room of the Company | Field visits | Institutions and individuals | Guotai Haitong Securities, TF Securities, Zheshang Securities, etc. | Investor communication | For details, please refer to the Record Sheet of Investor Relations Activities on January 21 and 22, 2026 published by the Company at https://irm.cninfo.com.cn/ and at www.cninfo.com.cn. |
IV. Quarterly Financial Statements
(I) Financial statements
1. Consolidated balance sheet
Prepared by: Huadong Medicine Co., Ltd.
| Item | Closing balance | Opening balance |
| Current assets: | ||
| Monetary funds | 3,734,865,777.19 | 4,978,052,188.84 |
| Deposit reservation for balance | ||
| Lendings to banks and other financial institutions | ||
| Trading financial assets | ||
| Derivative financial assets | ||
| Notes receivable | 6,213,394.05 | |
| Accounts receivable | 11,076,591,135.34 | 8,985,587,945.31 |
| Receivables financing | 332,387,014.92 | 460,578,206.16 |
| Prepayments | 508,155,787.14 | 445,803,941.09 |
| Premium receivable | ||
| Reinsurance accounts receivable | ||
| Reinsurance contract reserve receivable | ||
| Other receivables | 609,897,223.80 | 517,535,129.39 |
| Incl.: Interest receivable | ||
| Dividends receivable | 223,608.84 | 223,608.84 |
| Financial assets purchased for resale | ||
| Inventory | 5,327,579,147.01 | 5,535,765,919.86 |
| Incl.: Data resources | ||
| Contract assets | ||
| Assets held for sale | ||
| Non-current assets due within one year | 75,464,880.54 | 75,464,880.54 |
| Other current assets | 139,274,907.01 | 222,343,329.23 |
| Total current assets | 21,804,215,872.95 | 21,227,344,934.47 |
| Non-current assets: | ||
| Loans and advances issued | ||
| Debt investments | ||
| Other debt investments | ||
| Long-term receivables | ||
| Long-term equity investment | 1,629,415,091.83 | 1,509,122,017.22 |
| Investment in other equity instruments | 682,132,315.02 | 681,006,253.76 |
| Other non-current financial assets | ||
| Investment property | 10,694,501.05 | 10,946,776.47 |
| Fixed assets | 4,389,958,201.12 | 4,470,264,264.88 |
| Construction in progress | 931,509,517.77 | 832,431,516.18 |
| Productive biological assets | ||
| Oil and gas assets | ||
| Right-of-use assets | 158,409,996.23 | 170,395,474.59 |
| Intangible assets | 3,922,211,412.97 | 3,849,691,624.59 |
| Incl.: Data resources | ||
| Development expenditure | 1,943,582,627.60 | 1,757,196,902.53 |
| Incl.: Data resources | ||
| Goodwill | 2,848,210,102.92 | 2,860,135,566.37 |
| Long-term deferred expenses | 18,776,159.14 | 19,541,767.43 |
| Deferred income tax assets | 385,084,524.44 | 385,084,524.45 |
| Other non-current assets | 1,183,842,241.90 | 1,264,874,697.98 |
| Total non-current assets | 18,103,826,691.99 | 17,810,691,386.45 |
| Total assets | 39,908,042,564.94 | 39,038,036,320.92 |
| Current liabilities: | ||
| Short-term borrowings | 1,714,508,902.52 | 1,621,903,523.77 |
| Borrowings from the central bank | ||
| Borrowings from other banks and other financial institutions | ||
| Trading financial liabilities | ||
| Derivative financial liabilities | ||
| Notes payable | 3,017,614,936.17 | 2,910,051,094.08 |
| Accounts payable | 4,591,952,103.81 | 5,059,850,765.02 |
| Advance receipts | 502,191.65 | 797,358.84 |
| Contract liabilities | 232,364,085.08 | 188,554,462.61 |
| Expense for financial assets sold for repurchase | ||
| Deposits taken and interbank deposits | ||
| Receivings from vicariously traded securities | ||
| Receivings from vicariously sold securities | ||
| Employee compensation payable | 237,138,507.68 | 411,598,841.94 |
| Taxes and dues payable | 553,756,331.70 | 563,317,023.92 |
| Other payables | 2,567,376,516.56 | 2,215,275,211.55 |
| Incl.: Interests payable | ||
| Dividends payable | 101,810,219.60 | 102,560,219.60 |
| Handling charges and commissions payable | ||
| Reinsurance accounts payable | ||
| Liabilities held for sale | ||
| Non-current liabilities due within one year | 82,978,800.49 | 108,871,732.55 |
| Other current liabilities | 34,942,891.80 | 10,443,641.94 |
| Total current liabilities | 13,033,135,267.46 | 13,090,663,656.22 |
| Non-current liabilities: | ||
| Provision for insurance contracts | ||
| Long-term borrowings | 251,619,962.82 | 252,034,854.55 |
| Bonds payable | ||
| Incl.: Preferred share | ||
| Perpetual bonds | ||
| Lease liabilities | 111,057,382.92 | 88,813,504.20 |
| Long-term payables | ||
| Long-term employee compensation payable | ||
| Estimated liabilities | 19,922,759.61 | 20,617,015.41 |
| Deferred revenue | 187,359,036.43 | 190,942,291.61 |
| Deferred income tax liabilities | 217,236,393.17 | 223,959,318.75 |
| Other non-current liabilities | ||
| Total non-current liabilities | 787,195,534.95 | 776,366,984.52 |
| Total liabilities | 13,820,330,802.41 | 13,867,030,640.74 |
| Owners' equity: | ||
| Share capital | 1,753,736,848.00 | 1,753,736,848.00 |
| Other equity instruments | ||
| Incl.: Preferred share | ||
| Perpetual bonds | ||
| Capital reserve | 2,416,510,921.20 | 2,416,358,618.64 |
| Less: Treasury share | ||
| Other comprehensive income | -74,836,933.54 | 5,770,687.07 |
| Special reserves | ||
| Surplus reserves | 1,616,443,486.39 | 1,616,443,486.39 |
| General risk reserves | ||
| Retained earnings | 20,021,219,710.05 | 19,019,030,352.89 |
| Total owners' equity attributable to the parent company | 25,733,074,032.10 | 24,811,339,992.99 |
| Minority interests | 354,637,730.43 | 359,665,687.19 |
| Total owners' equity | 26,087,711,762.53 | 25,171,005,680.18 |
| Total liabilities and owners' equity | 39,908,042,564.94 | 39,038,036,320.92 |
Legal representative: Lv Liang Officer in charge of accounting: Lv Liang Head of Accounting Department: Qiu Renbo
2. Consolidated income statement
Unit: RMB
| Item | Amount incurred in the current period | Amount incurred in the previous period |
| I. Total operating revenue | 11,183,450,824.27 | 10,735,787,899.82 |
| Incl.: Operating revenue | 11,183,450,824.27 | 10,735,787,899.82 |
| Interest income | ||
| Premiums earned | ||
| Handling charges and commissions revenue | ||
| II. Total operating costs | 9,992,872,896.34 | 9,620,007,130.43 |
| Incl.: Operating costs | 7,387,443,870.04 | 7,206,598,136.26 |
| Interest expenditure | ||
| Handling charges and commissions expenditure | ||
| Surrender value | ||
| Net payments for insurance claims | ||
| Net provision for insurance liabilities | ||
| Expense for insurance policy dividends | ||
| Reinsurance expenses | ||
| Taxes and surcharges | 67,774,008.09 | 57,265,200.91 |
| Selling expenses | 1,820,619,488.78 | 1,470,753,504.47 |
| Management expenses | 371,395,501.48 | 355,395,350.66 |
| R&D expenses | 350,365,327.14 | 515,376,918.47 |
| Financial expenses | -4,725,299.19 | 14,618,019.66 |
| Incl.: Interest expense | 19,176,576.84 | 25,924,507.30 |
| Interest income | 20,155,981.89 | 27,812,843.06 |
| Plus: Other incomes | 31,230,304.02 | 73,641,636.88 |
| Investment income (loss expressed with "-") | -22,310,345.97 | -42,624,149.61 |
| Incl.: Investment income in associates and joint ventures | -7,510,017.34 | -28,249,462.69 |
| Income from derecognition of financial assets measured on the basis of amortized costs | ||
| Exchange earnings (loss expressed with "-") | ||
| Net income of exposure hedge (loss expressed with "-") | ||
| Income from changes in fair value (loss expressed with "-") | ||
| Credit impairment loss (loss | ||
| expressed with "-") | ||
| Asset impairment loss (loss expressed with "-") | ||
| Proceeds from disposal of assets (loss expressed with "-") | 534,949.84 | -14,540,990.32 |
| III. Operating profit (loss expressed with "-") | 1,200,032,835.82 | 1,132,257,266.34 |
| Plus: Non-operating revenue | 1,256,954.75 | 769,095.39 |
| Less: Non-operating expenses | 9,095,444.64 | 28,075,417.91 |
| IV. Total profit (total loss expressed with "-") | 1,192,194,345.93 | 1,104,950,943.82 |
| Less: Income tax expense | 195,032,945.55 | 190,966,760.40 |
| V. Net profit (net loss expressed with "-") | 997,161,400.38 | 913,984,183.42 |
| (I) Classification by continuity of operation | ||
| 1. Net profits from continuing operations (net loss expressed with "-") | 997,161,400.38 | 913,984,183.42 |
| 2. Net profit from discontinued operations (net loss expressed with "-") | ||
| (II) Classification by ownership | ||
| 1. Net profit attributable to the owners of the parent company | 1,002,189,357.16 | 914,708,484.70 |
| 2. Minority interest income | -5,027,956.78 | -724,301.28 |
| VI. Other comprehensive income (net of tax) | -80,607,620.61 | 82,044,972.47 |
| Other comprehensive income attributable to the owner of the parent company (net of tax) | -80,607,620.61 | 82,044,972.47 |
| (I) Other comprehensive income that cannot be reclassified into the profits and losses | ||
| 1. Change from re-measurement of defined benefit plan | ||
| 2. Other comprehensive income that cannot be included in the profits and losses under the equity method | ||
| 3. Changes in fair value of investment in other equity instruments | ||
| 4. Changes in fair value by the enterprise's credit risks | ||
| 5. Others | ||
| (II) Other comprehensive income that will be reclassified into the profits and losses | -80,607,620.61 | 82,044,972.47 |
| 1. Other comprehensive income that can be transferred to the profit and loss under the equity method | ||
| 2. Changes in fair value of investments in other debt investments | ||
| 3. Financial assets reclassified into other comprehensive income | ||
| 4. Provision for credit impairment of other debt investments | ||
| 5. Cash flow hedging reserves | ||
| 6. Converted difference in foreign currency financial statements | -80,607,620.61 | 82,044,972.47 |
| 7. Others | ||
| Other comprehensive income attributable to minority shareholders (net of tax) | ||
| VII. Total comprehensive income | 916,553,779.77 | 996,029,155.89 |
| Total comprehensive income attributable to the owner of the parent company | 921,581,736.55 | 996,753,457.17 |
| Total comprehensive income attributable to minority shareholders | -5,027,956.78 | -724,301.28 |
| VIII. Earnings per share: | ||
| (I) Basic earnings per share | 0.5715 | 0.5224 |
| (II) Diluted earnings per share | 0.5715 | 0.5213 |
If there is a business combination under common control in this period, the net profit of the combined party before the combination is RMB 0.00, and the net profit of the combined party in the previous period is RMB 0.00. Legal representative: Lv Liang Officer in charge of accounting: Lv Liang Head of Accounting Department: Qiu Renbo
3. Consolidated cash flow statement
Unit: RMB
| Item | Amount incurred in the current period | Amount incurred in the previous period |
| I. Cash flows from operating activities: | ||
| Cash received from selling goods and providing services | 10,376,323,259.38 | 9,882,552,619.72 |
| Net increase in deposits from customers as well as banks and other financial institutions | ||
| Net increase in borrowings from the central bank | ||
| Net increase in borrowings from other financial institutions | ||
| Cash received from the original insurance contract premium | ||
| Net cash received from reinsurance business | ||
| Net increase in deposits and investments from policyholders | ||
| Cash received from interests, handling charges and commissions | ||
| Net increase in borrowings from banks and other financial institutions | ||
| Net increase in funds from repurchase business | ||
| Net cash received from securities trading agency | ||
| Refund of taxes and fees received | 2,570,131.00 | 2,055,460.55 |
| Receipt of other cash relating to operating activities | 124,934,981.83 | 230,013,343.26 |
| Subtotal of cash inflows from operating activities | 10,503,828,372.21 | 10,114,621,423.53 |
| Cash paid for purchase of goods and receipt of labor services | 7,960,726,465.36 | 7,695,820,108.31 |
| Net increase in customer loans and advance payments | ||
| Net increase in deposits with the central bank and interbank | ||
| Cash for payment of the original insurance contract | ||
| Net increase in lendings to banks and other financial institutions | ||
| Cash paid for interests, handling charges and commissions | ||
| Cash for payment of dividends on policies | ||
| Cash paid to and for employees | 1,542,554,152.98 | 1,441,219,423.87 |
| Various taxes and fees paid | 709,327,509.54 | 671,816,951.08 |
| Payment of other cash relating to operating activities | 1,143,556,006.96 | 1,138,493,634.15 |
| Subtotal of cash outflows from operating activities | 11,356,164,134.84 | 10,947,350,117.41 |
| Net cash flow from operating activities | -852,335,762.63 | -832,728,693.88 |
| II. Cash flows from investing activities: | ||
| Cash received from investment recovery | ||
| Cash received from obtaining investment income | 43,350,000.00 | |
| Net cash recovered from disposal of fixed assets, intangible assets and other long-term assets | 74,063.51 | 9,751,907.00 |
| Net cash received from disposal of subsidiaries and other business units | ||
| Receipt of other cash relating to investing activities | ||
| Subtotal of cash inflows from investing activities | 74,063.51 | 53,101,907.00 |
| Cash paid for the purchase and construction of fixed assets, intangible assets and other long-term assets | 261,855,876.92 | 637,322,382.41 |
| Cash paid for investment | 129,618,537.85 | 61,618,925.00 |
| Net increase in pledged loans | ||
| Net cash paid for acquisition of subsidiaries and other business entities | ||
| Payments of other cash relating to investing activities | ||
| Subtotal of cash outflows from investing activities | 391,474,414.77 | 698,941,307.41 |
| Net cash flows from investing activities | -391,400,351.26 | -645,839,400.41 |
| III. Cash flows from financing activities: | ||
| Cash received by absorbing investment | ||
| Incl.: Cash received by subsidiaries from minority shareholders' investment | ||
| Cash received from obtaining borrowings | 1,131,688,831.32 | 1,289,998,848.00 |
| Receipt of other cash relating to financing activities | 800,000.00 | 146,000,000.00 |
| Subtotal of cash inflows from financing activities | 1,132,488,831.32 | 1,435,998,848.00 |
| Cash paid for debt repayment | 1,047,678,831.32 | 1,279,708,605.45 |
| Cash paid to distribute dividends, profits or pay interest | 37,291,974.45 | 17,579,298.66 |
| Incl.: Dividends and profits paid by subsidiaries to minority shareholders | ||
| Payment of other cash relating to financing activities | 12,306,031.36 | 225,549,581.73 |
| Subtotal of cash outflows from financing activities | 1,097,276,837.13 | 1,522,837,485.84 |
| Net cash flow from financing activities | 35,211,994.19 | -86,838,637.84 |
| IV. Effect of exchange rate changes on cash and cash equivalents | -4,179,294.34 | -3,115,685.50 |
| V. Net increase in cash and cash equivalents | -1,212,703,414.04 | -1,568,522,417.63 |
| Plus: Opening balance of cash and cash equivalents | 4,735,921,663.90 | 4,990,151,186.68 |
| VI. Closing balance of cash and cash equivalents | 3,523,218,249.86 | 3,421,628,769.05 |
(II) Situation of relevant items of financial statements at the beginning of the current year after the initial implementation of adjustment of the New Accounting Standards in 2026
□Applicable Not applicable
(III) Audit report
Has the First Quarterly Financial Report been audited?
□Yes No
The Company’s First Quarterly Financial Report has not been audited.
股票
板块
用户
资讯
评论 (0)